Medicare AdvantagePrior AuthMedium impact
MA08.125d, Lurbinectedin (Zepzelca®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jun 1, 2026
We identified it
Jun 19, 2026
Summary
Policy MA08.125d updates medical necessity criteria for Lurbinectedin (Zepzelca®), a chemotherapy agent used in small cell lung cancer treatment. This recent change (effective June 1, 2026) modifies coverage requirements for this specialty pharmaceutical on Medicare Advantage plans. The billing team must review and implement new prior authorization and documentation requirements to ensure compliant claim submission.
Action Required
By May 15, 2026: Oncology and hematology staff must review the full policy text at the provided URL to identify specific medical necessity criteria updates for Lurbinectedin (J9218). Update prior authorization protocols in the billing system to reflect new requirements. Provide training to billing team, providers, and clinical staff on updated documentation requirements for Zepzelca® claims. Effective June 1, 2026: All Lurbinectedin claims submitted to Medicare Advantage plans must comply with the new medical necessity criteria. Ensure prior authorization is obtained before administering or billing this drug. Claims submitted without proper documentation of medical necessity or prior authorization will be denied by Medicare Advantage plans.